Irene M. Ghobrial, MD, of Dana-Farber Cancer Institute, talks about PROMISE—her screening study for people at high-risk of developing precursor conditions of multiple myeloma—and how this and other trials have been altered in the wake of the pandemic, as well as what might be considered a silver lining to the crisis. Filmed March 30, 2020.
For community oncologists treating patients with multiple myeloma during the COVID-19 pandemic, what resources and clinical pearls would you suggest?
Recorded April 24, 2020.
Because of the COVID-19 pandemic, has your management strategy changed for post-transplant consolidation and maintenance therapy in patients with multiple myeloma?
Recorded April 24, 2020.
Mikkael A. Sekeres, MD, of the Cleveland Clinic, talks about the ways in which social distancing and viral fears have affected the way he delivers treatment for his patients, as well as the effect on their psyches—and his. Recorded April 10, 2020.
As a result of COVID-19, has your decision model for front-line therapy changed for patients with multiple myeloma who are either transplant-eligible or ineligible?
Recorded April 24, 2020.
For community oncologists treating patients with chronic myeloid leukemia or chronic lymphocytic leukemia during the COVID-19 pandemic, what resources and clinical pearls would you suggest?
Recorded April 24, 2020.
